

Confidence In Network Meta Analysis - CINeMA 2.0.0

- Project: **HFpEF network meta-analysis**

Heterogeneity

Define clinically important size of effect: Odds ratio

Relative effect estimates below **1.000** and above **1.000** are considered clinically important.

Importance of heterogeneity depends on the variability of effects in relation to a clinically important size of effect

The estimated value of between-study variance for the network meta-analysis is **0.000**

Comparison ACEI:ARB
Evidence: mixed

NMA estimate: **0.831**

95% intervals for NMA estimate

Confidence interval:

Prediction interval: **(0.433,1.594)**
(0.353,1.952)

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison ACEI:Placebo
Evidence: mixed

NMA estimate: **0.845**

95% intervals for NMA estimate

Confidence interval:

Prediction interval: **(0.448,1.595)**
(0.368,1.944)

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison ARB:ARNI
Evidence: mixed

NMA estimate: **1.036**

95% intervals for NMA estimate

Confidence interval:

Prediction interval: **(0.882,1.217)**
(0.839,1.279)

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison ARB:Placebo
Evidence: mixed

NMA estimate: **1.018**

95% intervals for NMA estimate

Confidence interval:

Prediction interval: **(0.877,1.180)**
(0.837,1.236)

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison**Beta blockers:Placebo****Evidence: mixed**NMA estimate: **0.588****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.363,0.953)**interval: **(0.312,1.108)**Prediction interval extends into clinically important effects in **both** directions

Heterogeneity judgment

Major concerns **Comparison Digoxin:Placebo****Evidence: mixed**NMA estimate: **0.999****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.744,1.342)**interval: **(0.679,1.471)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison MRA:Placebo****Evidence: mixed**NMA estimate: **0.910****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.756,1.096)**interval: **(0.714,1.161)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison Placebo:SGLT-2****Evidence: mixed**NMA estimate: **1.063****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.918,1.232)**interval: **(0.877,1.289)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison**Placebo:Vericiguat 10mg****Evidence: mixed**NMA estimate: **0.452****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.181,1.127)**interval: **(0.136,1.499)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison****Placebo:Vericiguat 15mg****Evidence: mixed**NMA estimate: **0.697****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.261,1.860)**interval: **(0.192,2.526)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison****Vericiguat 10mg:Vericiguat 15mg****Evidence: mixed**NMA estimate: **1.542****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.680,3.499)**interval: **(0.527,4.516)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison****ACEI:ARNI****Evidence: indirect**NMA estimate: **0.861****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.440,1.684)**interval: **(0.357,2.075)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison**Evidence: ACEI:Beta blockers indirect**NMA estimate: **1.437****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.647,3.193)**interval: **(0.505,4.094)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison ACEI:Digoxin****Evidence: indirect**NMA estimate: **0.846****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.420,1.703)**interval: **(0.338,2.118)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison ACEI:MRA****Evidence: indirect**NMA estimate: **0.929****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.479,1.799)**interval: **(0.390,2.211)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison ACEI:SGLT-2****Evidence: indirect**NMA estimate: **0.899****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.468,1.725)**interval: **(0.382,2.113)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison**ACEI:Vericiguat 10mg****Evidence: indirect**NMA estimate: **0.382****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.126,1.163)**interval: **(0.089,1.645)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison****ACEI:Vericiguat 15mg****Evidence: indirect**NMA estimate: **0.589****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.183,1.897)**interval: **(0.127,2.730)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison****Evidence: ARB:Beta blockers indirect**NMA estimate: **1.731****95% intervals for NMA estimate**

Confidence interval:

Prediction **(1.044,2.869)**interval: **(0.892,3.359)**Prediction interval extends into clinically important effects in **both** directions

Heterogeneity judgment

Major concerns **Comparison ARB:Digoxin****Evidence: indirect**NMA estimate: **1.018****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.732,1.416)**interval: **(0.661,1.570)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison **ARB:MRA**
Evidence: indirect

NMA estimate: **1.118**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.882,1.418)**
interval: **(0.819,1.527)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison **ARB:SGLT-2**
Evidence: indirect

NMA estimate: **1.082**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.878,1.333)**
interval: **(0.823,1.423)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison **ARB:Vericiguat 10mg**
Evidence: indirect

NMA estimate: **0.460**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.182,1.161)**
interval: **(0.137,1.549)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison **ARB:Vericiguat 15mg**
Evidence: indirect

NMA estimate: **0.709**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.263,1.914)**
interval: **(0.193,2.608)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison**Evidence: ARNI:Beta blockers indirect**NMA estimate: **1.670****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.983,2.840)**interval: **(0.833,3.350)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison ARNI:Digoxin****Evidence: indirect**NMA estimate: **0.983****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.681,1.419)**interval: **(0.607,1.591)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison ARNI:MRA****Evidence: indirect**NMA estimate: **1.079****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.810,1.438)**interval: **(0.741,1.572)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison ARNI:Placebo****Evidence: indirect**NMA estimate: **0.982****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.789,1.223)**interval: **(0.737,1.309)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison ARNI:SGLT-2
Evidence: indirect

NMA estimate: **1.044**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.802,1.359)**

interval: **(0.739,1.476)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison ARNI:Vericiguat 10mg
Evidence: indirect

NMA estimate: **0.444**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.173,1.136)**

interval: **(0.129,1.523)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison ARNI:Vericiguat 15mg
Evidence: indirect

NMA estimate: **0.685**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.251,1.872)**

interval: **(0.183,2.560)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison Beta blockers:Digoxin
Evidence: indirect

NMA estimate: **0.588**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.334,1.036)**

interval: **(0.280,1.236)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison**Evidence: Beta blockers:MRA indirect**NMA estimate: **0.646****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.385,1.084)**interval: **(0.328,1.274)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison****Beta blockers:SGLT-2****Evidence: indirect**NMA estimate: **0.625****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.377,1.036)**interval: **(0.322,1.213)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns **Comparison****Beta blockers:Vericiguat 10mg****Evidence: indirect**NMA estimate: **0.266****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.095,0.747)**interval: **(0.068,1.031)**Prediction interval extends into clinically important effects in **both** directions

Heterogeneity judgment

Major concerns **Comparison****Beta blockers:Vericiguat 15mg****Evidence: indirect**NMA estimate: **0.410****95% intervals for NMA estimate**

Confidence interval:

Prediction **(0.137,1.224)**interval: **(0.098,1.721)**Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison Digoxin:MRA
Evidence: indirect

NMA estimate: **1.098**

95% intervals for NMA estimate

Confidence interval:

Prediction interval: **(0.775,1.555)**
(0.695,1.733)

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison Digoxin:SGLT-2
Evidence: indirect

NMA estimate: **1.062**

95% intervals for NMA estimate

Confidence interval:

Prediction interval: **(0.764,1.477)**
(0.690,1.636)

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison Digoxin:Vericiguat 10mg
Evidence: indirect

NMA estimate: **0.452**

95% intervals for NMA estimate

Confidence interval:

Prediction interval: **(0.173,1.180)**
(0.128,1.592)

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison Digoxin:Vericiguat 15mg
Evidence: indirect

NMA estimate: **0.697**

95% intervals for NMA estimate

Confidence interval:

Prediction interval: **(0.250,1.941)**
(0.182,2.671)

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns

Comparison **MRA:SGLT-2**
Evidence: indirect

NMA estimate: **0.968**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.764,1.226)**

interval: **(0.709,1.320)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns ▾

Comparison
MRA:Vericiguat 10mg

Evidence: indirect

NMA estimate: **0.411**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.162,1.046)**

interval: **(0.121,1.398)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns ▾

Comparison
MRA:Vericiguat 15mg
Evidence: indirect

NMA estimate: **0.635**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.234,1.723)**

interval: **(0.171,2.352)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns ▾

Comparison
SGLT-2:Vericiguat 10mg
Evidence: indirect

NMA estimate: **0.425**

95% intervals for NMA estimate

Confidence interval:

Prediction **(0.168,1.073)**

interval: **(0.126,1.432)**

Confidence and prediction intervals **agree** in relation to clinically important effect

Heterogeneity judgment

No concerns ▾

Comparison**SGLT-2:Vericiguat 15mg****Evidence: indirect**NMA estimate: **0.656****95% intervals for NMA
estimate**

Confidence interval:

Prediction **(0.243,1.769)**interval: **(0.178,2.410)**Confidence and prediction
intervals **agree** in relation to
clinically important effect

Heterogeneity judgment

No concerns